---
title: The Effect of Non-invasive Auricular Acupoint Stimulation on Slow Transmission Constipation
nct_id: NCT06680882
overall_status: NOT_YET_RECRUITING
phase: PHASE2
sponsor: The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
study_type: INTERVENTIONAL
primary_condition: Slow Transmission Constipation
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06680882.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06680882"
ct_last_update_post_date: 2024-11-08
last_seen_at: "2026-05-12T06:56:54.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Non-invasive Auricular Acupoint Stimulation on Slow Transmission Constipation

**Official Title:** The Second Hospital Affiliated Anhui University of Chinese Medicine

**NCT ID:** [NCT06680882](https://clinicaltrials.gov/study/NCT06680882)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
- **Conditions:** Slow Transmission Constipation
- **Start Date:** 2024-11-07
- **Completion Date:** 2025-11-01
- **CT.gov Last Update:** 2024-11-08

## Brief Summary

Objective To examine the therapeutic effect and safety of non-invasive auricular acupoint stimulation application on patients with slow transmission constipation.

Methods In a randomized clinical trial, 60 patients diagnosed with slow transit constipation (STC), ranging in age from 40 to 75 years, were allocated into two distinct cohorts: a study group and a control group. The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride, while the control group, also consisting of 30 patients, was administered prucapride as a monotherapy. To assess the efficacy of the interventions, various parameters were monitored, including serum levels of Neuropeptide Y (NPY), nitric oxide (NO), fecal water content, and gastrointestinal (GI) transit. The comparative therapeutic outcomes were determined by calculating symptom scores.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria: ① Conformity to the diagnostic benchmarks for STC as delineated in the Rome IV criteria; ② Absence of ingestion of any medication influencing gastrointestinal motility within the preceding three months; ③ Provision of informed consent after a comprehensive understanding of the study's objectives; ④ An age range of 40 to 75 years.

\-

Exclusion Criteria: ① Withdrawal from the therapeutic regimen; ② Auricle or ear canal pathologies; ③ Organic defecation disorder; ④ Pregnant or lactating.

\-
```

## Arms

- **study group** (EXPERIMENTAL) — The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
- **control group** (OTHER) — also consisting of 30 patients, was administered prucapride as a monotherapy.

## Interventions

- **Auricular Acupoint Stimulation +prucapride** (OTHER) — The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
- **prucapride** (DRUG) — was administered prucapride as a monotherapy

## Primary Outcomes

- **overall efficacy rate** _(time frame: From enrollment to the end of treatment at one week)_ — Symptoms were assessed both one week prior to and one week following treatment. The defecation time (scored as follows: 0 for ≤5 minutes; 1 for \>5 to ≤15 minutes; 2 for \>15 to ≤25 minutes; and 3 for \>25 minutes) and the inter defecation interval (scored as the number of hours divided by 24) were recorded. The efficacy index was calculated using the formula: \[(pretreatment score - posttreatment score)/ pretreatment score\] × 100%.

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06680882.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06680882*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*